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M A J O R A R T I C L E
Pediatric Epstein-Barr Virus Carriers With or Without
Tonsillar Enlargement May Substantially Contribute
to Spreading of the Virus
Martina Hug,1 Marcus Dorner,1,a Franziska Zucol Fro¨hlich,1 Claudine Gysin,2 Diego Neuhaus,3 David Nadal,1,b
and Christoph Berger1,b
Divisions of 1Infectious Diseases and Hospital Epidemiology, 2Otolaryngology, and 3Anesthesia, University Children’s Hospital of Zurich, Zurich,
Switzerland
Background. Human-to-human transmission of the persistent infection establishing Epstein-Barr virus (EBV)
occurs via saliva. Tonsils act as important portal of entry and exit of EBV. The contagiousness of pediatric EBV
carriers and the role played by tonsillar enlargement (TE) are not known.
Methods. We compared EBV shedding in mouthwash samples from pediatric EBV carriers with or without
TE to that in mouthwash samples from pediatric patients with infectious mononucleosis (IM), the symptomatic
form of primary infection if delayed after the age of 5 years. EBV DNA was quantified by polymerase chain
reaction, and contagiousness was assessed using the cord lymphocyte transformation assay.
Results. EBV carriers with TE shed EBV DNA at an almost similar frequency (although in lower amounts)
as pediatric patients with acute IM but more frequently ( ) and in higher amounts ( ) than EBVP ! .001 Pp .038
carriers without TE. EBV DNA levels in mouthwash samples from EBV carriers with TE mirrored levels in tonsils
and gradually declined after tonsillectomy. Almost half of the mouthwash samples from pediatric EBV carriers
contained infectious EBV.
Conclusions. Pediatric EBV carriers—in particular, those with TE—may considerably contribute to the spread-
ing of EBV in industrialized countries.
More than 90% of the adult population carry Epstein-
Barr virus (EBV), a human gammaherpesvirus that es-
tablishes latency in memory B cells to persist in the
host [1]. Thus, EBV is one of the most successfully
spreading viruses [2]. The members of the population
involved in the spreading of EBV are only incompletely
defined.
Human-to-human transmission of EBV occurs main-
ly via saliva [1]. Palatine tonsils act as an important site
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used by EBV for invasion of the host and as a reservoir
[3, 4]. Oropharyngeal shedding of EBV via saliva is linked
to virus reactivation from latency [1] and is increased in
immunocompromised hosts, including human immu-
nodeficiency virus type 1–infected patients [5] and al-
lograft recipients [6]. Although these individuals are
spreaders of EBV, the bulk of overall EBV spreading likely
originates from the much larger immunocompetent pop-
ulation. Reactivation of EBV in immunocompetent hosts
may be initiated by terminal differentiation of EBV-car-
rying memory B cells to plasma cells in tonsils [7]. Re-
current or chronic infection within tonsils results in their
enlargement, and the effect that tonsillar enlargement
(TE) in EBV carriers has on EBV shedding is largely
unknown.
Adults with acute infectious mononucleosis (IM) in-
variably shed large amounts of EBV DNA and/or in-
fectious particles in saliva for several months [8–10],
in contrast with healthy adults, who shed EBV at vary-
ing percentages and in smaller amounts [10–14]. Al-
though acute IM manifests in up to 50% of adolescents
and 70% of adults experiencing primary EBV infection
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[15, 16], the vast majority of primary EBV infections occur
during early childhood [17, 18]. Then, EBV acquisition seems
to exhibit an asymptomatic or an unspecific clinical course.
Little is known about EBV shedding by pediatric patients with
IM or EBV carriers: 2 studies from Africa showed that EBV
DNA was present in saliva from up to 90% of children [19,
20], and 1 study from Japan detected EBV DNA in saliva from
38% of healthy children !6 years of age with unknown EBV
carrier status [21].
In the present study, we aimed to determine the frequency
and amount of oral EBV shedding among pediatric EBV car-
riers with or without TE in comparison to that in children
with acute and convalescent IM from an industrialized coun-
try. Our results indicate that children constitute a potentially
important source of EBV transmission.
METHODS
Subjects and study design. Children with acute IM or EBV
seropositivity undergoing tonsillectomy for TE or children with
no TE (NTE) undergoing other elective surgery at University
Children’s Hospital of Zurich were prospectively enrolled after
written informed consent was obtained. Mouthwash and pe-
ripheral blood samples were collected at enrollment, and
mouthwash samples from patients with IM or from EBV car-
riers with TE were obtained 3 and 6 months later. From carriers
with TE we obtained the tonsils. Diagnosis of acute IM was
established on the basis of the presence of fever, TE, hepato-
splenomegaly, and generalized lymph node enlargement, plus
detectable immunoglobulin M (IgM) to viral capsid antigen
(VCA) and absent immunoglobulin G (IgG) to EBV nuclear
antigen in serum (Immuno-DOT; GenBio). EBV carriers were
defined as EBV-seropositive children (presence of IgG to VCA
in the absence of IgM to VCA). Fifty-seven (60%) of the re-
cruited patients with TE and 14 (50%) of those with NTE were
EBV seropositive and were included in the study. Indications
for tonsillectomy were obstructive sleep apnea syndrome (84%)
and recurrent tonsillitis (16%). These children had no history
of IM within the past 12 months. The study protocol was
approved by the institutional ethics committee.
Peripheral blood. Peripheral blood mononuclear cells
(PBMCs) and plasma were isolated from venous blood by
means of Vacutainer CPT tubes (BD), in accordance with the
manufacturer’s instructions, and stored separately at 80C
until use.
Palatine tonsils. Tonsillar mononuclear cells (TMCs) were
collected by Ficoll-Isopaque density gradient centrifugation
(Leucosep; Greiner Bio-One) after dissociation of the tissue.
Mouthwash samples. Samples from patients with TE or
NTE were obtained during anesthesia before surgery by rins-
ing the mouth with 5 mL of phosphate-buffered saline or, at
follow-up visits and from patients with IM, after gargling with
5 mL of phosphate-buffered saline. To detect infectious virus
in the cell-free compartment [8, 12, 22], debris and bacteria
were removed by low-speed centrifugation (1260 g for 10 min).
The supernatant was stored at 80C until use, whereby a
fraction was supplemented with 10% heat-inactivated fetal calf
serum before being stored for later use in transformation assays.
After thawing, the samples were passed through a filter with a
pore size of 0.45 mm (Millipore).
DNA extraction. DNA was extracted from PBMCs or ton-
sils (20–100 mg/sample) and, after addition of herring sperm
DNA (Invitrogen), from plasma or mouthwash samples by
means of the QIAamp DNA Mini kit (Qiagen) [23]. DNAse
treatment was performed in accordance with the manufac-
turer’s instructions (Applied Biosystems).
Quantitative polymerase chain reaction assay. EBV DNA
levels were determined by the TaqMan (Applied Biosystems)
real-time polymerase chain reaction (PCR) technique, using 2
PCR primer-probe systems targeting the conserved EBV BamHI
W region [23] and the conserved LMP1 exon 3 region [24].
Serial dilutions of a plasmid containing the targeted sequence
were included in every PCR run as an internal control and for
calibration [23]. The BamHI W system has a higher sensitivity
than the LMP1 system and, after correction for multiple copies
of the BamHI W repeats, correlated with the values determined
by LMP1 quantitative PCR (qPCR) [24]. Values !2 DNA cop-
ies/reaction (the limit of detection) were regarded as negative
[3, 23, 24]. The number of cells was quantified by qPCR tar-
geting the single-copy human hydroxymethylbilane synthase
gene (HMBS) [3, 4].
Cell culture and virus stock. Primary cells and the EBV-
producer cell line B95.8 [25] were maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium supplemented with
10% fetal bovine serum, 1% l-glutamine, and 1% penicillin-
streptomycin (Gibco) [26].
Transformation assay. Cord blood mononuclear cells
(CBMCs) were isolated by Ficoll separation. CBMCs ( )62 10
and mouthwash samples were mixed 1:1 in a total volume of
1 mL and spinoculated for 1 h at 800 g at 24C [8, 20]. After
washing with RPMI 1640, CBMCs were incubated in 96-well
plates at 37C. Half of the medium was changed every 3 days
for 6 weeks, when growth of cells indicated CBMC transfor-
mation. For each CBMC donor, transformation was controlled
by inoculation with B95.8 supernatant [8, 25].
Statistical analysis. The x2, Kruskal-Wallis, and Mann-
Whitney U tests (Prism 4; GraphPad Software) were used to
compare groups regarding the frequency of detection and levels
of EBV DNA. The Spearman correlation coefficient was used
to assess correlations between EBV DNA levels in distinct com-
partments. Differences with were regarded as statisticallyP ! .05
significant.
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Figure 1. Frequency of Epstein-Barr virus (EBV) DNA detection in
mouthwash samples, peripheral blood mononuclear cells (PBMCs), and
plasma from pediatric patients with acute infectious mononucleosis (IM)
( ), pediatric EBV carriers with tonsillar enlargement (TE) ( ),np 9 np 57
and pediatric EBV carriers with no TE (NTE) ( ). EBV DNA wasnp 14
detected by quantitative polymerase chain reaction. Detection of EBV
DNA in mouthwash samples from patients with IM and those with TE
was not significantly different ( ).Pp .58
RESULTS
Frequency of detectable EBV DNA in mouthwash, PBMC, and
plasma samples from pediatric patients with IM and EBV
carriers. Patients with acute IM exhibit TE and shed EBV via
saliva [8, 9, 11, 27, 28]. We asked whether pediatric EBV carriers
with TE shed EBV in saliva more frequently than do carriers
with NTE and whether this is mirrored in peripheral blood.
Therefore, by qPCR we assessed and compared the frequencies
of detectable EBV DNA in mouthwash, PBMC, and plasma
samples from 9 children with acute IM (age range, 2.9–13.9
years; median age, 6 years; mean age, 7.3 years), from 57 EBV
carriers with TE (age range, 2.8–14.8 years; median age, 6.0
years; mean age, 6.3 years), and from 14 EBV carriers with
NTE (age range, 1.5–15.8 years; median age, 8.8 years; mean
age, 8.3 years).
We detected EBV DNA in all mouthwash ( ), PBMCnp 9
( ), and plasma ( ) samples from patients with acutenp 9 np 7
IM (Figure 1). Partly in contrast, we detected EBV DNA in 47
mouthwash samples (88%) and 30 PBMC samples (57%) from
53 carriers with TE but in no plasma samples (0%) from 57
carriers with TE. In greater contrast, we detected EBV DNA in
7 mouthwash samples (50%) from 14, in 6 PBMC samples
(46%) from 13, and in no plasma samples (0%) from 14 carriers
with NTE (Figure 1). Thus, EBV carriers with TE had detectable
EBV DNA in mouthwash samples at a frequency similar to that
in patients with acute IM and at a frequency significantly higher
than that in carriers with NTE ( ). This suggests thatPp .001
TE is associated with more frequent EBV shedding than NTE.
EBV DNA levels in mouthwash samples from pediatric pa-
tients with IM and EBV carriers. We wondered whether EBV
DNA levels in mouthwash samples from carriers with TE dif-
fered from those in mouthwash samples from patients with
acute IM or from carriers with NTE. We found EBV DNA
levels between 55 and 21,592 copies/mL of mouthwash among
patients with acute IM, between !2 and 14,744 copies/mL of
mouthwash among carriers with TE ( ), and betweenPp .002
!2 and 1377 copies/mL of mouthwash among carriers with
NTE ( , for the comparison with carriers with TE)Pp .038
(Figure 2). The median EBV DNA level in mouthwash samples
from carriers with TE was ∼17-fold lower than that for patients
with acute IM but was ∼5-fold higher than that for carriers
with NTE (Figure 2).
Next, we asked whether these differences were reflected in
PBMCs. We found EBV DNA levels between 1.8 and 1249
copies/104 PBMCs for patients with acute IM, between 0.1 and
71 copies/104 PBMCs for carriers with TE ( ), and be-P ! .001
tween 0.4 and 56 copies/104 PBMCs for carriers with NTE
( ) (Figure 2). The median EBV DNA level in PBMCsPp .001
from carriers with TE was ∼150-fold lower than that for pa-
tients with acute IM but was rather similar to that in PBMCs
from carriers with NTE (Figure 2).
These observations suggest that TE in carriers is associated
with increased EBV DNA shedding, a process apparently not
mirrored by increased EBV DNA levels in PBMCs.
EBV DNA levels in mouthwash samples, tonsils, and PBMCs
from pediatric EBV carriers with TE. We investigated wheth-
er mouthwash EBV DNA levels mirror the levels in autologous
enlarged tonsils. We found a highly statistically significant cor-
relation between mouthwash levels and levels in TMCs (rp
; ) (Figure 3A), suggesting that the amount of EBV0.65 P ! .001
in tonsils may dictate the amount shed in saliva. Furthermore,
we found a highly statistically significant correlation between EBV
DNA levels in tonsils and PBMCs ( ; ) (Figurerp 0.71 P ! .001
3B). This suggests that the amount of EBV in enlarged tonsils
may influence the amount circulating in PBMCs.
Next, we asked whether EBV DNA levels in mouthwash sam-
ples and PBMCs correspond in carriers with TE. We found a
highly statistically significant correlation ( ; )rp 0.69 P ! .001
(Figure 3C). Thus, the amount of EBV in enlarged tonsils seems
to influence the amount in saliva and PBMCs. We found no
correlation between EBV DNA levels in mouthwash and PBMC
samples from patients with acute IM ( ; )rp0.04 Pp .69
(data not shown) but did find a correlation for carriers with
NTE ( ; ) (data not shown), suggesting thatrp 0.57 Pp .044
the amounts of EBV shed in saliva and in PBMCs are closely
related in EBV carriers, in striking contrast to patients with
acute IM.
EBV DNA levels in mouthwash samples from pediatric pa-
tients with IM and EBV carriers over time. We asked whether
the frequency of detectable EBV DNA and EBV DNA levels
would diminish after tonsillectomy, analogous to what is ob-
served in adult convalescent IM patients [29]. The proportion
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Figure 2. Epstein-Barr virus (EBV) DNA levels in mouthwash samples (left panel ) or peripheral blood mononuclear cells (PBMCs) (right panel ) from
pediatric patients with acute infectious mononucleosis (IM) ( ), pediatric EBV carriers with tonsillar enlargement (TE) ( ), and pediatric EBVnp 9 np 57
carriers with no TE (NTE) ( ). EBV DNA levels were determined by quantitative polymerase chain reaction. Horizontal lines in the box plotnp 14
indicate medians; the bottoms and tops of the boxes indicate lower and upper quartiles, respectively; and the brackets indicate minimal and maximal
values.
of pediatric patients with IM who had detectable EBV DNA in
mouthwash samples diminished over time, from 100% during
the acute phase, to 6 (87%) of 7 patients 3 months later, and
to 3 (60%) of 5 patients 6 months later (Figure 4A). EBV DNA
levels ranged from 55 to 21,592 copies/mL of mouthwash dur-
ing the acute phase and then decreased to a range of !2 to 931
copies/mL of mouthwash 3 months later ( ) and to aPp .005
range of !2 to 268 copies/mL of mouthwash 6 months later
( ) (Figure 4A). Among carriers with TE, the frequencyPp .004
of detectable EBV DNA in mouthwash samples diminished
from 88% at tonsillectomy to 19 (66%) of 29 children 3 months
later and to 8 (47%) of 17 children 6 months later. EBV DNA
levels ranged from !2 to 14,744 copies/mL of mouthwash at
tonsillectomy and then decreased to a range of !2 to 3400
copies/mL of mouthwash 3 months later ( ) and to aPp .035
range of !2 to 2905 copies/mL of mouthwash 6 months later
( ) (Figure 4B). These results illustrate a decrease in theP ! .001
frequency of detectable EBV DNA and in EBV DNA levels shed
in saliva by children after IM or tonsillectomy due to TE.
Transformation of CBMCs by mouthwash. To investigate
the infectivity of saliva, we determined transformation effi-
ciency using CBMCs. First, we ascertained that mouthwash
does not markedly influence the transformation efficiency of
inoculated EBV (data not shown).
Second, we compared EBV DNA levels with the presence of
infectious EBV using serial dilutions of B95.8 culture super-
natant. Supernatant containing at least 4500 EBV DNA copies/
mL resulted in a transformation efficiency of 100%. The inoc-
ulated amount of EBV DNA and the transformation efficiency
correlated significantly ( ; ) (Figure 5A).rp0.82 Pp .034
Third, we investigated the transformation capacity of mouth-
wash samples from 6 patients with IM. The mean EBV DNA
level in mouthwash samples from patients with acute IM result-
ing in transformation of CBMCs was 3330 EBV DNA copies/
mL (range, 120–50,300 EBV DNA copies/mL). Five samples
(83%) resulted in transformation of CBMCs, whereby the in-
oculated amount of EBV DNA and the transformation efficiency
correlated significantly ( ; ) (Figure 5B). Therp0.85 Pp .033
mean EBV DNA level in mouthwash samples 1–6 months after
acute IM was 120 EBV DNA copies/mL (range, 2–736 EBV DNA
copies/mL). Four samples (67%) resulted in transformation of
CBMCs (Figure 5B). Thus, saliva from the majority of patients
with acute IM or during the first 6 months thereafter contains
infectious EBV with transformation capacity.
Fourth, we asked whether mouthwash samples from carriers
with TE are infectious. The mean EBV DNA level in 10 mouth-
wash samples corresponded to 400 EBV DNA copies/mL
(range, 20–27,510 EBV DNA copies/mL). Four samples (40%)
resulted in transformation of CBMCs (Figure 5C). We also
tested mouthwash samples from these 10 individuals 3–6
months after tonsillectomy. The mean EBV DNA level was 36
EBV DNA copies/mL (range, 2–4500 EBV DNA copies/mL).
Three samples (30%) resulted in transformation of CBMCs
(Figure 5C). Finally, we asked whether mouthwash samples
from carriers with NTE were capable of infecting and trans-
forming CBMCs. We inoculated CBMCs with mouthwash sam-
ples from 6 randomly chosen individuals. The mean EBV DNA
level was 36 EBV DNA copies/mL (range, 2–1347 EBV DNA
copies/mL). Three samples (50%) resulted in transformation
of CBMCs (Figure 5D).
Fifth, we performed DNAse digestion of mouthwash samples
from 8 patients with IM and 3 carriers with TE to distinguish
between total detectable EBV DNA (including naked frag-
ments) and encapsidated DNA (suggesting infectious virus)
[30]. Digestion with DNAse I reduced total EBV DNA levels
determined by qPCR by 90%–95%, which were still detectable
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Figure 3. Correlation between Epstein-Barr virus (EBV) DNA levels in
mouthwash samples, tonsillar mononuclear cells (TMCs), and peripheral
blood mononuclear cells (PBMCs) from pediatric EBV carriers with tonsillar
enlargement. A, EBV DNA levels in TMCs versus levels in mouthwash
samples. B, EBV DNA levels in PBMCs versus levels in TMCs. C, EBV
DNA levels in PBMCs versus mouthwash. EBV DNA levels were deter-
mined by quantitative polymerase chain reaction.
Figure 4. Epstein-Barr virus (EBV) DNA levels in mouthwash samples
from pediatric patients during acute infectious mononucleosis (IM) and
3 and 6 months (+ 3m and + 6m, respectively) later (A) or from pediatric
EBV carriers with tonsillar enlargement at tonsillectomy (TE a. t.) and 3
and 6 months after tonsillectomy (t. + 3m and t. + 6m, respectively) (B ).
in 4 of 8 mouthwash samples from patients with IM and in
the 3 mouthwash samples from carriers with TE with the high-
est EBV DNA levels. Three of these 4 mouthwash samples from
patients with IM and 2 of the 3 mouthwash samples from
carriers with TE with detectable EBV DNA after DNAse di-
gestion induced CBMC transformation. This indicated that
mouthwash from patients with IM and from carriers with TE
contain infectious EBV.
Taken together, mouthwash samples from a considerable
proportion of carriers with TE before and 3–6 months after
tonsillectomy as well as from carriers with NTE contain infec-
tious EBV with transformational potential. These results suggest
that EBV carriers represent a considerable source of infectious
EBV, irrespective of TE.
DISCUSSION
This study investigated oral EBV shedding by pediatric EBV
carriers with or without TE versus pediatric patients with IM
from an industrialized country. We found that (1) pediatric
carriers with TE orally shed EBV at a frequency almost similar
to that of the invariably shedding pediatric patients with acute
IM, although in lower amounts; (2) oral shedding is more
frequent and occurs in larger amounts in carriers with TE than
with NTE; (3) EBV DNA levels in mouthwash samples from
carriers with TE mirror levels in tonsils; (4) oral EBV DNA
shedding by carriers with TE decline after tonsillectomy; and
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Figure 5. Transforming Epstein-Barr virus (EBV) in culture supernatants
of wild-type EBV strain B95.8 and in mouthwash samples in relation to
EBV DNA levels. A, Wild-type EBV strain B95.8. B, Pediatric patients with
acute infectious mononucleosis (IM) and 1–6 months later (IM 1 + 6m).
C, Pediatric EBV carriers with tonsillar enlargement (TE) before tonsil-
lectomy (TEat OP) and 3–6 months after tonsillectomy (TE +3 to 6m). D,
Pediatric EBV carriers with no TE (NTE). In panel C, only 1 of 4 samples
without transformation and no detection of EBV DNA and only 1 of 2
samples without transformation and 36 EBV DNA copies/mL are visible.
qPCR, quantitative polymerase chain reaction.
(5) almost half of mouthwash samples from carriers contain
infectious EBV. Our results indicate that children constitute an
important source of EBV transmission and may considerably
contribute to the spreading of EBV in industrialized countries.
A major finding was that the vast majority of carriers with
TE shed EBV DNA orally. The frequency of 88% was as high
as the up to 90% reported among children from Africa [19]
and was almost as high as the 100% among pediatric patients
with acute IM found here. Children in Africa were found to
shed higher EBV DNA levels than their mothers [19]. Oral EBV
DNA shedding by adult carriers from industrialized countries
ranged from 50% to 100% [14, 21, 31, 32]. Here, pediatric
carriers with TE orally shed EBV significantly more frequently
than did carriers with NTE. These results argue that pediatric
carriers in industrialized countries may orally shed EBV less
frequently than those in developing countries and that TE,
similar to malaria [33], results in an increased frequency of
shedding. Further indication that TE augments oral EBV DNA
shedding is provided by our observation of significantly higher
levels in mouthwash samples from carriers with TE than with
NTE. Nevertheless, the levels in mouthwash samples from car-
riers with TE were significantly lower than those in mouthwash
samples from acute IM patients. This suggests that, at least in
children, maximal oral EBV shedding occurs in primary EBV
infection manifesting as IM. In patients with IM, replication
of EBV seems to follow distinct patterns relative to those in
EBV carriers, independently of TE—as indicated by the detec-
tion of EBV DNA in the extracellular and cellular compart-
ments of the peripheral blood of patients with IM, in contrast
with the detection (if any) in the cellular compartment only
for carriers, as shown here.
Another finding of interest was that EBV DNA levels in
mouthwash samples from carriers with TE mirrored the lev-
els in their tonsils and correlated with levels in PBMCs. Our
observation of a similar strong correlation between levels in
mouthwash samples and PBMCs for carriers with NTE but not
for patients with acute IM again indicates that EBV replication
patterns differ between primary infection and the carrier state.
The results also indicate that in pediatric carriers the amount
of EBV shed in saliva and the level of EBV in PBMCs are tightly
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related, in striking contrast to the situation for acute IM. In
adult carriers, Yao et al [31] also found a correlation between
EBV DNA levels in mouthwash samples and those in PBMCs,
but Hadinoto et al [29] found no correlation between EBV in
saliva and peripheral blood memory B cells from 8 subjects.
Although the number and percentage of B cells circulating in
blood, the biological activity of tonsils, the number of upper
respiratory tract infections, the time elapsed since primary EBV
infection, and possibly EBV shedding [19] are different between
children and adults, the EBV DNA levels in PBMCs from our
pediatric carriers were similar to those reported for adults [14,
34, 35]. Thus, it is unclear whether the correlation between
orally shed EBV DNA and levels in PBMCs are specific for
pediatric carriers.
The gradual decay of oral EBV DNA shedding by carriers
after tonsillectomy corroborates the potential of TE in con-
tributing to the shedding and spreading of EBV. The decay
resembles that seen in pediatric patients with IM during con-
valescence, when TE diminishes. The decay observed here in
pediatric patients with IM is similar to that seen in adult pa-
tients with IM in a recent study by Hadinoto et al [29] but
contrasts with findings of other studies showing shedding of
constant EBV DNA levels for at least 6 months [9, 10].
Almost half of the pediatric EBV carriers with viral DNA in
mouthwash samples shed infectious EBV. This is relevant to
the circulation of EBV in the community. The infectious po-
tential of mouthwash samples from carriers did not correlate
with EBV DNA levels. These findings contrasted with those for
supernatants of wild-type EBV cultures and mouthwash sam-
ples from patients with acute IM. Fafi-Kremer et al [9] sug-
gested that EBV shed by adults after acute IM is less infectious.
Thus, one possible explanation for the disparity between acute
IM and convalescent IM or the EBV carrier state in children
observed here could relate to infectious properties rather than
solely to the quantity of EBV shed.
It is well established that EBV DNA levels determined by
qPCR need not correspond to numbers of infectious EBV par-
ticles [30, 36]. Unencapsidated EBV DNA may be a confounder
that results in overestimation of the amount of EBV, as has
been demonstrated using DNAse digestion [30, 36–39]. DNAse
digestion and CBMC transformation by mouthwash samples
from children with IM or TE provided evidence that DNAse-
resistant (ie, contagious) EBV is present in mouthwash from
pediatric patients with IM or TE. On the basis of the trans-
formation of CBMCs, infectious EBV was demonstrated in
mouthwash samples from children with IM, TE, or NTE. In
pediatric EBV carriers, contagiousness was independent of EBV
DNA levels, in contrast to patients with IM. Notably, mouth-
wash samples from single carriers with NTE and without de-
tectable EBV DNA transformed CBMCs. This implies that, de-
spite the high sensitivity of the qPCR assay (lower limit of
detection, 2 EBV DNA copies/mL), infectious particles were
present in mouthwash.
In conclusion, our findings suggest that pediatric EBV car-
riers may represent an important source of EBV spreading, es-
pecially among young children, given their frequent oral shed-
ding of infectious virus and their rather frequent exchange of
saliva resulting from their age-related behavior.
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